
Designated States (unless otherwise indicated, for every kind of regional protection available): AROPO (BW, GH, GI, KE, LS, NW, MW, NA, SD, SL, SZ, TZ, UB, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published: with international search report
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Title: ACE-INHIBITORY WHEY HYDROLYSATES

Abstract: The invention relates to compounds with an antihypertensive effect. More in particular, the invention relates to releasing ACE (angiotensin I - converting enzyme)-inhibitory peptides from whey proteins. The invention provides a method for enzymatically producing a protein hydrolysate with angiotensin-converting enzyme (ACE)-inhibitory activity, characterized by treatment of a beta-lactoglobulin (BLG) -containing substrate with a broad-spectrum endopeptidase in a first reaction step followed by treatment with a proline-specific endopeptidase in a second reaction step. The invention also relates to ACE-inhibitory hydrolysates obtainable according to such a method and use of the hydrolysates.
Title: ACE-inhibitory whey hydrolysates

The invention relates to compounds with an antihypertensive effect. More in particular, the invention relates to releasing ACE (angiotensin I-converting enzyme)-inhibitory peptides from whey proteins.

Hypertension or high blood pressure is an important risk factor for the development of heart and vascular diseases, which are the main cause of death in the Western world. It is estimated that 1 in 5 adults in the world suffer from hypertension. We refer to hypertension if the systolic blood pressure is on average 140 mm Hg or higher, and/or if the diastolic blood pressure is on average 90 mm Hg or higher. In general, lower values apply to pregnant women. Children have a blood pressure which is normally below 120/70 mm Hg. Hypertension accelerates the ageing of the arteries and increases the load on the heart. The older an artery, the greater the chance that it is damaged. Hypertension damages all arteries of the organism, which can lead to a heart attack, a stroke or damage of the kidneys. In order to avoid this, hypertension needs to be treated with medication.

Conventionally, hypertension is prevented by administering antihypertensive medicines and by adjusting the dietary habits and lifestyle. ACE plays an important role in maintaining the blood pressure. In the human body, ACE brings about the formation of angiotensin II from angiotensin I. Increase of the amount of angiotensin II in the blood has inter alia the following effects: (1) constriction of the blood vessels (vasoconstriction) and associated hypertension; (2) release of aldosterone from the adrenal cortex and vasopressin (antidiuretic hormone = ADH) from the neurohypophysis; these two hormones cause the kidneys to retain more water, so that the blood volume increases; and (3) increase of the feeling of thirst, so that more water is drunk.
Blocking of ACE and prevention of an increase of the amount of angiotensin II in the blood result in a decrease of blood pressure in hypertensive patients. Therefore ACE inhibitors are important in the control of hypertension in medicine. However, a drawback of the many pharmaceutical preparations with synthetic ACE inhibitors which are on the market is that they often have unpleasant side effects, such as a dry cough.

In the literature, in the past 10 years, bioactive peptides potentially incorporated in milk proteins have regularly been written about. All kinds of hydrolysates have been manufactured from milk proteins, either with the aid of enzymes or in situ through fermentation processes (cheese, yoghurt), in which these bioactive peptides have been demonstrated. One of the most important properties of these bioactive peptides is blood pressure decrease through the inhibition of the ACE reaction. ACE-inhibitory peptides – either as protein hydrolysate or formed in situ through fermentation – are attractive 'natural' antihypertensive compounds.

Particular peptides are found to be very effective in the prevention and the treatment of hypertension. It is not exactly known what structural characteristics ACE-inhibitory peptides should satisfy, but there is some similarity between the peptides which already have a proven ACE inhibition. These are generally short peptides (2-4 amino acids) with a hydrophobic amino acid on the C-terminal side. Also, the amino acid proline is often mentioned which is then terminally, usually C-terminally present on the peptide.

The Japanese firm Calpis Co. Ltd has obtained ACE-inhibitory peptides through fermentation. These are usually small peptides which are characterized by the presence of the amino acid proline and a high ACE-inhibitory activity. The active peptides obtained by fermentation mainly consist of the sequences which have proline in their structures; namely Val-Pro-Pro or Ile-Pro-Pro (Nakamura, Y. et al. (1996), J. Dairy Sci.
78; 777-783). Other peptides with an antihypertensive activity are described in *inter alia* Nouchikusangiyou, Snow Brand, Symbicom AB and Nisshin Flour Milling Co Ltd [ref 10-17].

A number of companies have recently marketed hydrolysates and/or fermented products with an ACE-inhibitory activity, in combination with another property. Thus, WO 01/85984 (Davisco) describes a method for releasing ACE-inhibitory peptides from whey proteins with the aid of different types of industrially obtainable proteases, including porcine trypsin. Here, incidentally, not a protein concentrate was taken as a starting material, but a purified whey protein product, whey protein isolates. One hydrolysate, obtained through action of trypsin, was moreover found to have an antihypertensive effect after oral administration to rats. This hydrolysate has a degree of hydrolysis (%DH) of about 6% and has been marketed within the product range BIOZATE (*www.daviscofoods.com*). The degree of hydrolysis indicates to what extent peptide bonds of a protein have been hydrolyzed as a result of an enzymatic hydrolysis reaction. A %DH of 50 indicates that a particular enzyme has hydrolyzed 50% of the peptide bonds available for that enzyme. In addition, an additional property for such a type of hydrolysate has been described (WO 03/063778), where, in addition to ACE inhibition, the peptide mixture is also said to have a cholesterol (low-density lipoprotein) lowering effect.

WO 01/32906 of Valio describes the fermentation of casein with the aid of lactic acid bacteria to release peptides having an antihypertensive effect. The product produced by this means has been marketed as a fermented product under the name Evolus. This product is also said to have an additional property, namely increasing or enhancing the absorption of minerals under the influence of these peptides. These peptides are also characterized by high concentration of Val-Pro-Pro or Ile-Pro-Pro peptides, similar to the product of CALPIS.
It is obvious that it is important for a measurable blood pressure
decrease that the active peptides / hydrolysates have sufficient
ACE-inhibitory activity. The ACE-inhibitory activity of an ACE-inhibitor,
such as a peptide or hydrolysate, is usually expressed as an IC50 value.
This value indicates the concentration of peptide / hydrolysate necessary to
reduce the ACE activity by 50%. The lower the IC50 value of an ACE
inhibitor, the stronger the ACE-inhibitory activity.

The object of the invention is to provide hydrolysates with a strong
ACE-inhibitory activity.

To this end, the invention provides a method for enzymatically
producing a protein hydrolysate with angiotensin-converting enzyme
(ACE)-inhibitory activity comprising treatment of a beta-lactoglobulin
(hereinafter: BLG)-enriched protein with a broad-spectrum endoprotease in
a first reaction step followed by treatment with a proline-specific protease in
a second reaction step. Such a method yields a protein hydrolysate with an
IC50 value which is at least three times lower compared with the known
hydrolysates with ACE-inhibitory activity (see Table 1). In the first reaction
step, the protein substrate is hydrolyzed to a fairly high degree of
hydrolysis, usually about 10 to about 15%, in order to make
proline-containing peptides available as a substrate for a proline-specific
protease, so that, in the second step, peptides with a C-terminal
proline-residue are formed.

A two-step hydrolysis process according to the invention with a first
hydrolysis step with a broad-spectrum protease and a second hydrolysis step
with a proline-specific protease applied to a BLG-rich protein substrate has
not been described before. Though the use of BLG or a BLG-rich whey
protein concentrate as a source of ACE-inhibitory peptides is known, in this,
a proline-specific protease has not been used before. Abubakar et al.
determined the ACE-inhibitory activity of whey protein hydrolysates
prepared with 7 different enzymes: trypsin, proteinase-K, actinase-E,
thermolysin, papain, pepsin and chymotrypsin. The enzyme specificity was found to have a great effect on the ACE-inhibitory activity of the resulting hydrolysates, and the biological activity was found to come from the 4 dominant proteins in whey (BLG; alpha-lactoglobulin, ALA; blood serum albumin, BSA; and immunoglobulins, Ig) (Abubakar et al. 1996, Tokohu J. Agric. Res., 47(1-2):1-8). More recent work of Abubakar et al. describes the identification of 9 peptide sequences, of which BLG tripeptide (f78-80; Ile-Pro-Ala) exhibited the strongest antihypertensive activity in hypertensive rats (Abubakar et al. 1998, J. Dairy Sc., 12:3131-3138).

Mullally et al. isolated the peptide (f142-148) from a hydrolysate of bovine BLG obtained with trypsin. This peptide has an IC50 value of 43 μmol/L (Mullally et al. 1997. FEBS Letters, 402:99-101). Also, hydrolysates of BLG-enriched whey protein isolate have been prepared and tested for their ACE-inhibitory activity. WO 01/85984 (Davisco International Foods, Inc) describes the manufacture of ACE-inhibitory hydrolysates by means of porcine trypsin or a bacterial protease applied to different commercial whey protein concentrates. Here, a comparison is made between the ACE-inhibitory activity of a hydrolysate obtained from a standard whey protein isolate (94% protein) obtained by ion exchange chromatography (BiPRO, Davisco Foods International, LeSueur, MN) and a BLG-enriched whey protein isolate. The hydrolysates obtained from the purified standard isolate were found to have a lower IC50 value (290-450 μg/ml) than the hydrolysates obtained from the BLG-enriched isolate (530-900 μg/ml). This was surprising, since peptide (f142-148) from BLG, which was used as a reference in the study, had the lowest IC50 value (40 μg/ml). So, just like the invention, WO01/85984 describes the manufacture of an ACE-inhibitory hydrolysate from a BLG-enriched whey protein concentrate. However, in WO01/85984, the manufacture involves one single hydrolysis step (either with trypsin, or with bacterial protease) whereas a method according to the present invention is characterized by a two-step hydrolysis process with a
broad-spectrum protease followed by a proline-specific protease. In addition, the ACE-inhibitory activity of a hydrolysate according to the invention proves to be much higher than those of known (hydrolysates of) whey protein concentrates (see Table 3 below).

The present finding that hydrolysis of BLG with a proline-specific endoprotease (PSE) in a method according to the invention yields a hydrolysate with a relatively low IC50 value is very surprising. As stated hereinabove, particular powerful ACE-inhibitory tripeptides (e.g. Val-Pro-Pro or Ile-Pro-Pro) contain a high concentration of (terminal) proline residues. However, none of the known ACE-inhibitory peptides coming from BLG (see Table 2) contains a C-terminal proline residue, and only a few peptides (f(32-40); f(78-80); f(142-146) and f(142-148)) contain an internal proline residue. In addition, the total protein content in BLG is relatively low (5%) compared with, for instance, casein (11%), a much used milk protein for the formation of ACE-inhibitory peptides by means of (lactic acid) fermentation. Thus, under action of a PSE, relatively few peptides with a terminal proline residue are created. It is therefore not obvious to use a proline-specific endoprotease to release ACE-inhibitory peptides from BLG. The invention now shows that, after the two-step treatment according to the invention, a BLG-based hydrolysate has a higher ACE-inhibitory activity than a casein hydrolysate, in spite of the fact that casein contains a higher content of proline (see Table 1). One could conclude from this that particular specific amino acid sequences with a terminal proline are determinative of the ACE-inhibitory activity, and not terminal proline-containing peptides in general.

Preferably, a method according to the invention is used on a substrate consisting of a mixture of proteins of which at least 25% is BLG, such as 30% or 35% BLG, preferably at least 40% BLG, such as 45%, 50% or 55%, more preferably at least 60% BLG, such as 65% or 70%. Also, (purified) BLG can be used as a substrate. However, it goes without saying that the
production costs of an ACE-inhibitory hydrolysate will be higher as a more purified protein substrate is used as a starting material.

A whey protein concentrate enriched with beta-lactoglobulin is an attractive starting material in a method according to the invention. A BLG-enriched WPC may be obtained by making the other whey proteins, mainly ALA, BSA and Ig, precipitate from a WPC by applying specific conditions. A particular combination of desalting, temperature and pH denatures the respective proteins, after which they aggregate and can be separated centrifugally or through membrane filtration.

Whey constitutes 80 to 90% of the total volume of milk entering the production process and contains about 50% of the nutrients of the original milk such as proteins, lactose, vitamins and minerals. In the past, whey has always been considered waste of the cheese industry, but the discharge of cheese whey causes large environmental problems. However, because the proteins have good functional properties, nowadays the interest in the use of whey for the extraction thereof is great. Only 0.55% of the whey consists of proteins. On a dry matter basis, this is 10%. The whey proteins are a heterogeneous mixture, of which the main proteins are β-lactoglobulin (50%), α-lactoglobulin (ALA; 20%), blood serum albumin (BSA; 5%) and immunoglobulins (Ig; 12%). In order to be able to increase the dry matter content of whey to at least approximately 50-60%, whey is concentrated or dried. A whey protein concentrate (WPC) is made by fractioning and concentrating whey by means of ultrafiltration. As further concentrating takes place, different levels of protein arise in the whey protein concentrate.

Industrially produced WPCs are classified into the categories low-protein WPC (protein content between 25-40%), medium-protein WPC (protein content between 45-60%) and high-protein WPC (protein content between 60-80%). The higher the protein content of a WPC, the more BLG is available in the concentrate for hydrolysis to ACE-inhibitory peptides. Since whey proteins consist for approximately 50% of BLG, a high-protein WPC
contains between 30-40% BLG, which is sufficient for use of such a WPC in a method according to the invention. However, the BLG content of low-protein and medium-protein WPCs is often too low. For WPCs with a protein content of about 55-60% or lower, it is therefore necessary to enrich for BLG. Suitable commercial WPCs include Domovictus 535 from BDI (35% protein of which 85% BLG); Hiprotal 880 from BDI (80% protein of which 50-55% BLG) and Hiprotal 580 (80% protein of which 80-85% BLG), all available from Borculo Domo Ingredients (BDI), Zwolle, the Netherlands.

As a broad-spectrum endoprotease in the first reaction step in a method according to the invention, different types of endoproteases can be used. Suitable endoproteases are of animal, vegetable or microbial origin. A microbial broad-spectrum endoprotease is preferred, since these are often easily commercially available at a relatively reasonable price. Chemically or genetically modified mutant proteases may be suitable as well. The broad-spectrum protease may be a serine protease or a metalloprotease, preferably an alkaline microbial protease. Examples of alkaline proteases are subtilisins (EC 3.4.21.62), in particular those coming from Bacillus spp., e.g. subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279) and chymotrypsin (EC 3.4.21.1), which preferably hydrolyze the peptide bond on the C-terminal side of hydrophobic amino acids such as Tyr, Trp, Phe and Leu. Also, in the first reaction step, a mixture of two or more endoproteases can be used. Suitable commercially available proteases comprise Alcalase™, Savinase™, Primase™, Everlase™, Esperase™ and Kannase™ (Novozymes A/S), Maxatase™, Maxacal™, Maxapem™, Properase™, Purafect™, Purafect OXP™, FN2™, and FN3™ (Genencor International Inc.), Corolase™ and Veron™ (AB Enzymes). Preferably, in the first reaction step, the enzyme Alcalase™ is used. In a further embodiment of the invention, as a broad-spectrum protease, an aspartate protease is used. Just like PSE, this enzyme has an acid pH optimum, which has the advantage that the pH does
not need to be adjusted after the first step. Optionally, the aspartate protease is used simultaneously with the PSE in a one-step hydrolysis. However, in that case, the fact should be taken into account that the broad-spectrum protease can also hydrolyze the PSE enzyme. The duration of the first reaction step depends on various factors, such as the enzyme and/or the substrate used. Preferably, hydrolyzing takes place until a degree of hydrolysis of at least 8% has been reached, more preferably at least 10%, such as 12% or 15%. For most of the broad-spectrum proteases mentioned, it holds true that, under the conditions suitable for that enzyme (pH, temperature, salt concentration and the like), such a degree of hydrolysis can be reached in a few hours.

After the first incubation step, the broad-spectrum endoprotease used is preferably inactivated to prevent the possibility of the PSE being hydrolyzed by the broad-spectrum protease in the second reaction step. Methods for enzyme inactivation are known to a skilled person, such as a heat treatment or use of a compound which can inhibit the enzyme activity.

The second reaction step is carried out with a proline-specific endopeptidase (PSE; EC 3.4.21.26). A suitable PSE for use in the method of the invention is, for instance, a proline-specific endoprotease of *A. niger*, such as the enzyme which is known in the market under the name EndoPro and which is described in WO 02/45524. In a further embodiment, in the second reaction step, a Proline-Specific Endoprotease of *Flavobacterium meningosepticum* is used.

Further, the invention provides a protein hydrolysate with angiotensin-converting enzyme (ACE)-inhibitory activity, obtainable with a method as described hereinabove. This hydrolysate is characterized by a strong ACE-inhibitory activity (see Table 3) and can therefore be used with advantage for inhibiting ACE activity in mammals, such as humans. A hydrolysate is also suitable for veterinary application, for instance in a cat or dog. Since inhibition of ACE has an antihypertensive effect *in vivo*, an
ACE-inhibitory hydrolysate can be used for the treatment of hypertension. A hydrolysate according to the invention can be processed into different products, such as liquid and dry products. If desired, downstream processing takes place, for instance in the form of an ultrafiltration (UF) treatment. The enzymes have a much larger molecular weight than the peptides and can be separated from the ACE-inhibitory peptides by means of UF. An additional advantage of a UF step is that the protein substrates which have not been degraded by the enzymes can also be separated from the biologically active hydrolysate.

It is assumed that, after oral intake, the peptides of a hydrolysate according to the invention end up in the stomach in intact or virtually intact form, to subsequently be taken up into the bloodstream. The broad-spectrum protease in the first reaction step of a method according to the invention has a broader substrate specificity than the brush border proteases in the intestinal wall, so that the hydrolysate according to the invention will not or hardly be hydrolyzed further after oral intake.

Optionally, a hydrolysate can be used in combination with other ACE inhibitors. In a further aspect of the invention, the ACE-inhibitory hydrolysate is preventively used to prevent hypertension, for instance in a person with a genetic disposition for hypertension or if medicines are used which cause hypertension as a side effect.

In addition to being effective with hypertension, ACE inhibitors also prove to be effective with heart failure. An ACE-inhibitory hydrolysate obtainable with a method according to the invention can therefore also be used with heart problems, for instance after a coronary to prevent recurrence.

Thus, the invention provides a treatment method for inhibiting ACE activity in a mammal, comprising the, preferably oral, administration of an ACE-inhibitory hydrolysate obtained according to the method of the
invention in an amount and with a frequency
the ACE activity.

Still another aspect of the present invention relates to a treatment
method to reduce symptoms of hypertension in a mammal, comprising the,
preferably oral, administration of a hydrolysate according to the invention
in an amount and with a frequency which is sufficient to inhibit the
symptoms of hypertension.

The invention also provides a composition comprising an
ACE-inhibitory hydrolysate according to the invention. Such a composition
with an ACE-inhibitory/antihypertensive activity is, for instance, a
pharmaceutical composition or a food or luxury food. An ACE-inhibitory
composition may have a solid or a liquid form. It is, for instance, a powder or
a tablet. Preferably, the ACE-inhibitory composition according to the
invention has a liquid form, such as a liquid milk product, a fruit juice or
another type of drinkable product which can *inter alia* be used to prevent or
treat hypertension.

Finally, the invention relates to the use of a composition according to
the invention for the preparation of a medicine for (prophylactically)
treating or preventing heart and vascular diseases. In particular, the
medicine to be prepared is a medicine for inhibiting ACE activity in a
mammal; a medicine for lowering the blood pressure; and/or a (prophylactic)
medicine for the occurrence of hypertension.

**EXPERIMENTAL PART**

1. *In vitro* measurement of ACE inhibition

The *in vitro* measurement of the ACE inhibitory activity of peptides
or another product (e.g. hydrolysate) was carried out as follows:

- Product is solved in measuring buffer consisting of borate, sodium
  chloride at pH 8.3
The substrate used for the measurement is Hippuryl-His-Leu from Sigma (H1635)

The ACE enzyme also comes from Sigma (A6778)

In a microcuvette, the substrate is incubated at 38°C with ACE enzyme and activity is spectrophotometrically monitored at 260 nm. In the presence of a peptide or hydrolysate to be tested, the inhibition of this activity is measured and expressed as the required amount of product needed to reduce the activity of the enzyme by 50%. This inhibition is determined for four different concentrations of the product to be measured.

**Experiment 1**

By means of a two-step hydrolysis process, ACE-inhibitory peptides are released from milk and whey proteins. In the first step, proteins were hydrolyzed with Alcalase (Novozymes), a broad-spectrum endoprotease of *Bacillus licheniformis*. To this end, 2.5 g of protein was solved in 50 ml water. The pH was set at 8.0 with 4 M NaOH. The reaction mixture was placed in a shaking water bath at a temperature of 60°C, after which the Alcalase (125µl pure enzyme) was added. The incubation was carried out for 4 hours.

At the end of the incubation period, the pH was brought to 5.0 with 4 M HCl. Then the broad-spectrum endoprotease was inactivated by an incubation of 5 minutes at 95°C. After this, the reaction mixture was ready for the second reaction step with the proline-specific endoprotease (PSE; also endopropyl hydrolase) EndoPro (DSM), a prolyl hydrolase of *Aspergillus niger*.

In order to obtain an enzyme/substrate ratio of 1U per gram of protein, 556µl EndoPro was added to the reaction mixture. Then incubation took place at 50°C in a shaking water bath. At times t=0, 60, 180, 360 en 1440 minutes, 200-µl samples were taken which were ten times diluted and
inactivated for 5 minutes at 95°C. Then the IC50 was determined of the hydrolysates obtained. The results are shown in Table 1. The protein substrates tested in this experiment are:

1. Domovictus 535 (BDI); a WPC with approximately 35% protein of which approximately 85% BLG
2. Hiprotal 580 (BDI); a WPC with 80% protein of which 80% BLG
3. Casein (Sigma)
4. Hiprotal 880 (BDI); a WPC with 80% protein of which 50% BLG
5. Beta-lactoglobulin (Sigma)
6. Alpha-lactalbumin (Sigma)

Table 1. Effect of treatment with proline-specific protease on ACE-inhibitory activity expressed as IC50 (µg/ml) of a protein substrate which was priorly treated with a broad-spectrum protease.

<table>
<thead>
<tr>
<th>Nr</th>
<th>Protein substrate</th>
<th>t=0 (min)</th>
<th>60</th>
<th>180</th>
<th>360</th>
<th>1440</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Domovictus 535</td>
<td>30.1</td>
<td>23.1</td>
<td>14.6</td>
<td>15.4</td>
<td>16.8</td>
</tr>
<tr>
<td>2</td>
<td>Hiprotal 580</td>
<td>20.1</td>
<td>13.8</td>
<td>7.6</td>
<td>11.2</td>
<td>14.7</td>
</tr>
<tr>
<td>3</td>
<td>Casein</td>
<td>64.2</td>
<td>35.2</td>
<td>27.2</td>
<td>23.2</td>
<td>19.8</td>
</tr>
<tr>
<td>4</td>
<td>Hiprotal 880</td>
<td>20.4</td>
<td>14.8</td>
<td>11.4</td>
<td>10.1</td>
<td>20.3</td>
</tr>
<tr>
<td>5</td>
<td>β-lactoglobulin</td>
<td>23.0</td>
<td>14.6</td>
<td>13.3</td>
<td>10.8</td>
<td>18.7</td>
</tr>
<tr>
<td>6</td>
<td>α-lactalbumin</td>
<td>26.9</td>
<td>24.5</td>
<td>26.9</td>
<td>24.0</td>
<td>20.8</td>
</tr>
</tbody>
</table>

After the first hydrolysis step with a broad-spectrum protease, the hydrolysates have an IC50 value varying from 20.1 µg/ml (Hiprotal 580) to 64.2 µg/ml (casein) as shown in column t=0 of Table 1. A follow-up treatment with a proline-specific endoprotease (PSE) for 60 minutes proves to be sufficient for Hiprotal 580, Hiprotal 880 and BLG to obtain an IC50 value below 15 µg/ml. A 3-hour incubation with PSE results in a further decrease of the IC50 values, while, for the Hiprotal 580 hydrolysate (also
referred to as Hydrohiprotal 980) a very low value of 7.6 µg/ml is obtained. Prolongation of the incubation period to 6 hours (t=360 min) with a proline-specific protease yields a further (small) decrease of the IC50 value for a number of protein substrates, while, for most substrates, the IC50 values show an increase again after a 24-hour incubation (t=1440 min). So, there appears to be an optimal incubation period, which could be explained by the fact that, with advanced hydrolysis, the peptides with ACE-inhibitory activity just formed are degraded further to peptides with a lower ACE-inhibitory activity.

The results in Table 1 show that hydrolysates prepared from a BLG-rich protein substrate (Domovictus 535, Hiprotal 580, Hiprotal 880 and BLG) according to a two-step procedure have an angiotensin-I-converting enzyme (ACE)-inhibitory activity which is about three times lower than has been observed so far for whey proteins. It further appears from the results of Table 1 that, in spite of a higher content of proline, the casein substrate (11% proline) yields a lower ACE-inhibitory activity after the two-step enzyme treatment than the hydrolysate on the basis of BLG-rich substrate (5% proline). Apparently, particular specific sequences with terminal proline are determinative of the ACE-inhibitory activity, and not only terminal proline-containing peptides.
Table 2: Literature IC50 values for ACE-inhibitory peptides from BLG.

<table>
<thead>
<tr>
<th>Peptide</th>
<th>IC50 (μmol/L)</th>
<th>IC50 (μg/mL)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>f(142-148)</td>
<td>43</td>
<td>40</td>
<td>(8)</td>
</tr>
<tr>
<td>f(78-80)</td>
<td>141</td>
<td>42</td>
<td>(9)</td>
</tr>
<tr>
<td>f(9-14)</td>
<td>580</td>
<td>390</td>
<td>(10)</td>
</tr>
<tr>
<td>f(15-20)</td>
<td>1682</td>
<td>1170</td>
<td>(10)</td>
</tr>
<tr>
<td>f(22-25)</td>
<td>1062</td>
<td>430</td>
<td>(11)</td>
</tr>
<tr>
<td>f(32-40)</td>
<td>635</td>
<td>616</td>
<td>(11)</td>
</tr>
<tr>
<td>f(102-103)</td>
<td>122</td>
<td>86</td>
<td>(12), (8)</td>
</tr>
<tr>
<td>f(81-83)</td>
<td>1029</td>
<td>404</td>
<td>(11)</td>
</tr>
<tr>
<td>f(94-100)</td>
<td>946</td>
<td>807</td>
<td>(11)</td>
</tr>
<tr>
<td>f(104-105)</td>
<td>350</td>
<td>97</td>
<td>(12), (8)</td>
</tr>
<tr>
<td>f(106-111)</td>
<td>788</td>
<td>515</td>
<td>(11)</td>
</tr>
<tr>
<td>f(142-146)</td>
<td>521</td>
<td>296</td>
<td>(11)</td>
</tr>
<tr>
<td>f(146-149)</td>
<td>1153</td>
<td>620</td>
<td>(12), (8)</td>
</tr>
</tbody>
</table>

5 Experiment 2

In this experiment, the in vitro ACE-inhibitory activity of a hydrolysate according to the invention (Hiprotal 580 treated for 20 hours with Alcalase followed by 3 hours of hydrolysis with proline-specific endoprotease) was compared with the ACE-inhibitory activity of the following commercially available hydrolysates, some of which have an antihypertensive effect.

- Hydrolysate DMV (standard protein hydrolysate for use in children's food)
- CE90 ACE (DMV product which is alleged to inhibit ACE; see www.dmv-international.com)
- Hydrolysate DI 3065 (Arla) (79.8% protein)
- Hydrolysate LE 80 BM (DMV) (81.7% protein)
- Hydrolysate CE 90 STL (DMV) (83.5% protein)
- Hydrolysate CE90 CPP (DMV) (87.0% protein)
The amount of protein present is between approximately 80 and 90% for the different products. Prior to the measurement of the ACE-inhibitory activity, 200-250 mg of product was dissolved in 20 ml of incubation buffer. After the product had dissolved completely, the solution was diluted 40x with incubation buffer. This dilution was used for determining the ACE-inhibitory activity. The results are shown in Table 3.

Table 3: Experimental IC50 values of commercial protein hydrolysates compared with an ACE-inhibitory hydrolysate according to the invention.

<table>
<thead>
<tr>
<th>Product</th>
<th>IC50 µg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrolysate of the invention</td>
<td>7.2</td>
</tr>
<tr>
<td>Hydrolysate DMV</td>
<td>47.0</td>
</tr>
<tr>
<td>CE90 ACE (DMV)</td>
<td>35.0</td>
</tr>
<tr>
<td>Hydrolysate DI 3065 (Arla)</td>
<td>33.0</td>
</tr>
<tr>
<td>Hydrolysate LE 80 BM (DMV)</td>
<td>44</td>
</tr>
<tr>
<td>Hydrolysate CE90 STL (DMV)</td>
<td>&gt;44</td>
</tr>
<tr>
<td>Hydrolysate CE90 CPP (DMV)</td>
<td>&gt;44</td>
</tr>
<tr>
<td>Evolus (VALIO)</td>
<td>&gt;44</td>
</tr>
<tr>
<td>Biozate (DAVISCO)</td>
<td>62</td>
</tr>
</tbody>
</table>

It appears from the results obtained that the IC50 values of some commercial products (DMV, Arla, Davisco) are in the same range as those of standard milk protein hydrolysates (30-40 µg/ml). Surprisingly, the IC50 value of the BLG-enriched hydrolysate according to the invention is about 5 times lower (approximately 7 µg/ml) and accordingly the activity is 5 times higher than other standard whey protein hydrolysates.
REFERENCES

1. Process for producing fermented milk containing angiotensin
   converting enzyme inhibitory peptide and process for producing milk serum;
   CALPIS CO., LTD.; EP 1142481A1

2. Process for producing fermented milk containing angiotensin
   converting enzyme inhibitory peptide and process for producing milk serum;
   CALPIS CO., LTD.; EP 1142481A4

3. HIGH YIELD PRODUCTION OF CURDS AND WHEY
   CONTAINING AN ACE INHIBITOR PEPTIDE (VAL-PRO-PRO AND/OR
   ILE-PRO-PRO) MADE UNDER STIRRING CONDITIONS; CALPIS CO.,
   LTD; NZ 0513305A

4. Process for producing granules containing angiotensin-
   converting enzyme inhibiting peptides; CALPIS CO., LTD.; US 6428812

5. GRANULES FOR ORAL ADMINISTRATION, PROCESS FOR
   PRODUCING THE SAME, AND TABLETS PRODUCED FROM THE
   GRANULES; CALPIS CO., LTD.; WO 0041677A1

6. GRANULATED MATERIAL, ITS PRODUCTION AND
   TABLET USING THE SAME; CALPIS CO., LTD.; JP 200020405A2

7. Method of purifying whey of lactic acid fermentation by
   electrodialysis; CALPIS CO. LTD; US 6204362

   enzyme inhibitory peptide corresponding to a tryptic fragment of bovine β-

9. Abubakar et al.; Structural analysis of new antihypertensive
   peptides derived from cheese whey protein by proteinase K digestion; J. of


12. NEW PEPTIDE AND ITS UTILIZATION; SNOW BRAND CO. LTD.; JP 0829088A2

13. Human β-casein, process for producing it and use thereof; SYMBICOM AKTIEBOLAG; US 5739407

14. GENE ENCODING A HUMAN BETA-CASEIN PROCESS FOR OBTAINING THE PROTEIN AND USE THEREOF IN AN INFANT FORMULA; SYMBICOM EP 0599978A1

15. GENE ENCODING A HUMAN BETA-CASEIN PROCESS FOR OBTAINING THE PROTEIN AND USE THEREOF IN AN INFANT FORMULA; SYMBICOM AKTIEBOLAG; WO 9304172A3

16. GENE ENCODING A HUMAN BETA-CASEIN PROCESS FOR OBTAINING THE PROTEIN AND USE THEREOF IN AN INFANT FORMULA; SYMBICOM AKTIEBOLAG; WO 9304172A2

17. New peptide and angiotensin transferase inhibitor; NISSHIN FLOUR MILLING CO. LTD; JP 04082898A2

18. Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals; DAVISCO; WO 0185984

19. Reducing cholesterol with hydrolyzed whey protein; DAVISCO; WO 03/063778 A2.

20. Process for producing a product containing antihypertensive tripeptides; VALIO; WO 01/32906.
CLAIMS


2. A method according to claim 1, characterized in that the substrate is a whey protein concentrate (WPC), preferably a WPC which has been enriched with beta-lactoglobulin (BLG).

3. A method according to claim 1 or 2, characterized in that the substrate contains at least 25%, preferably at least 35%, more preferably at least 60% BLG.

4. A method according to any one of claims 1-3, characterized in that the broad-spectrum endoprotease is a serine protease, a metallopeptase or an aspartate protease.

5. A method according to any one of claims 1-4, characterized in that the broad-spectrum endoprotease is a microbial protease, preferably a protease isolated from Bacillus lichenformis or Bacillus subtilis.

6. A method according to any one of claims 1-5, characterized in that the proline-specific endoprotease is a proline-specific endoprotease (PSE; EC 3.4.21.26).

7. A method according to any one of claims 1-6, wherein the first reaction step is carried out until a degree of hydrolysis of about 10 to about 15% has been reached.

8. A method according to any one of claims 1-7, wherein the second reaction step is carried out for at least 0.5 hour, preferably at least 1 hour, more preferably at least 2 hours, most preferably at least 3 hours.
9. A method according to any one of claims 1-8, wherein the second reaction step is carried out for at most 24 hours, preferably at most 16 hours, more preferably at most 10 hours.

10. A protein hydrolysate with angiotensin-converting enzyme (ACE)-inhibitory activity, obtainable with a method according to any one of claims 1-9.

11. A composition comprising a hydrolysate according to claim 10, preferably a pharmaceutical composition or a food or luxury food.

12. A composition according to claim 11, wherein the composition is a liquid product, such as a milk product or a fruit juice, or a solid product, such as a powder.

13. Use of a composition according to claim 11 or 12 for inhibiting ACE activity in a mammal, preferably a human, more preferably a human with hypertension or an increased risk of hypertension.

14. A treatment method for inhibiting ACE activity in a mammal, comprising the, preferably oral, administration of a composition according to claim 11 or 12 in an amount and with a frequency sufficient to inhibit the ACE activity.

15. A treatment method to reduce symptoms of hypertension in a mammal, comprising the, preferably oral, administration of a composition according to claim 11 or 12 in an amount and with a frequency sufficient to inhibit the symptoms of hypertension.

16. Use of a composition according to claim 11 or 12 for the preparation of a medicine for inhibiting ACE activity in a mammal; for lowering the blood pressure; and/or for preventing the occurrence of hypertension.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 C07K14/47 C12P21/06

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database and, where practical, search terms used)

EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:
  - "A" document defining the general state of the art which is not considered to be of particular relevance
  - "E" earlier document but published on or after the international filing date
  - "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O" document referring to an oral disclosure, use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed
  - "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
  - "S" document member of the same patent family

Date of the actual completion of the international search: 21 October 2005

Date of mailing of the international search report: 07/11/2005

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epc.nl, Fax: (+31-70) 340-3016

Authorized officer: Smalt, R
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 01/85984 A (DAVISCO INTERNATIONAL FOODS, INC; DAVIS, MARTIN, E; RAO, ANAND; GAUTHI) 15 November 2001 (2001-11-15) cited in the application the whole document</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>WO 03/063788 A (THE CLEVELAND CLINIC FOUNDATION; YI, TAOLIN) 7 August 2003 (2003-08-07) cited in the application the whole document</td>
<td></td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2415688 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1287159 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004519204 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 523036 A</td>
</tr>
</tbody>
</table>

W0 03063788 A 07-08-2003 NONE